RGEN vs ALNY Comparison: AI Score, Valuation, Performance and Upside
Compare Repligen and Alnylam by bioprocessing revenue recovery, RNA interference drug pipeline, clinical breadth, operating margins, and analyst upside.
Use this Repligen vs Alnylam Pharmaceuticals comparison to evaluate the key differences across valuation, growth, profitability, and risk before making an investment decision.
ALNY holds the edge across 3 of 5 key metrics in this comparison. RGEN has delivered stronger 1-year price return (+22.76% vs -17.92%), though ALNY has the better forward P/E setup (19.87x vs 54.93x for RGEN). Analyst consensus implies meaningfully more upside for ALNY (+61.82%) than for RGEN (+27.10%).
| Metric | RGEN | ALNY |
|---|---|---|
| AI score | 47.7 | 56.8 |
| AI rank | #622 | #259 |
| Latest close | $140.09 | $266.99 |
| 1M return | +10.68% | -6.78% |
| 6M return | -14.23% | -24.90% |
| 1Y return | +22.76% | -17.92% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | RGEN | ALNY |
|---|---|---|
| 1Y ago | $12.28K (+22.8%) started 2025-07-22 | $8.21K (-17.9%) started 2025-07-22 |
| 5Y ago | $6.8K (-32.0%) started 2021-07-22 | $14.69K (+46.9%) started 2021-07-22 |
| 10Y ago | $50.94K (+409.4%) started 2016-07-22 | $40.77K (+307.7%) started 2016-07-22 |
Hypothetical — past performance does not guarantee future results.
| Metric | RGEN | ALNY |
|---|---|---|
| Market cap | $7.9B | $35.65B |
| Trailing P/E | 152.27 | 68.11 |
| Forward P/E | 54.93 | 19.87 |
| Price/Sales | 10.35 | 8.32 |
| EV/Revenue | 10.22 | 8.31 |
| Analyst target | $178.05 | $432.04 |
| Target upside | +27.10% | +61.82% |
| Metric | RGEN | ALNY |
|---|---|---|
| Revenue growth | 14.80% | 96.40% |
| Earnings growth | 47.90% | N/A |
| EPS growth | +47.90% | N/A |
| FCF margin | +9.00% | +4.78% |
| Operating margin | N/A | N/A |
| Profit margin | 6.73% | 12.55% |
| ROIC proxy | 2.51% | 90.36% |
| Return on equity | 2.51% | 90.36% |
| Dividend yield | 0.00% | 0.00% |
| Beta | 1.06 | 0.27 |
| Debt/equity | 32.66 | 276.20 |
| Current ratio | 9.20 | 3.13 |
| Quick ratio | 7.45 | 2.88 |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | RGEN | ALNY |
|---|---|---|---|
| 1Y | Growth | +22.76% | -17.92% |
| CAGR | +22.77% | -17.93% | |
| Sharpe ratio | 0.58 | -0.46 | |
| Max drawdown | 40.28% | 45.65% | |
| Max daily drop | 8.31% | 6.87% | |
| Max wkly drop | 18.23% | 14.54% | |
| 5Y | Growth | -32.00% | +46.85% |
| CAGR | -7.42% | +7.99% | |
| Sharpe ratio | 0.01 | 0.29 | |
| Max drawdown | 68.27% | 45.65% | |
| Max daily drop | 13.22% | 17.10% | |
| Max wkly drop | 21.92% | 20.65% | |
| 10Y | Growth | +409.42% | +307.68% |
| CAGR | +17.68% | +15.09% | |
| Sharpe ratio | 0.49 | 0.44 | |
| Max drawdown | 68.27% | 59.95% | |
| Max daily drop | 14.44% | 48.49% | |
| Max wkly drop | 21.97% | 49.44% |
| Category | RGEN | ALNY |
|---|---|---|
| Company | RGEN | ALNY |
| Sector | N/A | N/A |
| Industry | N/A | N/A |
| Core business | N/A | N/A |
| Investor focus | N/A | N/A |
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.